ライフサイエンスコーパス: ovarian failure

1 llitus, Hashimoto's thyroiditis, and primary ovarian failure).

2 elopment of specialized therapies to prevent ovarian failure.

3 ) but could also without (type II) premature ovarian failure.

4 racterized by sensorineural hearing loss and ovarian failure.

5 fects, including kyphoscoliosis, and primary ovarian failure.

6 bnormal follicular development and premature ovarian failure.

7 to recover and are sterile, due to premature ovarian failure.

8 ion of its function in ovaries specially for ovarian failure.

9 subfertile and exhibited signs of premature ovarian failure.

10 ized with craniofacial defects and premature ovarian failure.

11 ivors of childhood cancer develop persistent ovarian failure.

12 an further develop parkinsonism or premature ovarian failure.

13 AS in older males and females, and premature ovarian failure.

14 eterioration often associated with premature ovarian failure.

15 and more common conditions such as premature ovarian failure.

16 ncentrations had returned to those seen with ovarian failure.

17 f chemotherapy and radiotherapy is premature ovarian failure.

18 sed significantly in the women who developed ovarian failure.

19 sponsible for environmental toxicant-induced ovarian failure.

20 other metabolic diseases, and for causes of ovarian failure.

21 vous system white matter disease and primary ovarian failure.

22 oss, 31.9% (95% CI, 28.0%-35.8%) for primary ovarian failure, 31.1% (95% CI, 27.3%-34.9%) for Leydig

23 licular initiation plays a role in premature ovarian failure, a common cause of infertility and prema

24 ight into the causes of idiopathic premature ovarian failure, a disease that burdens many infertile c

25 s well as long-term complications of primary ovarian failure and cognitive dysfunction, which are die

26 in young women facing the risk of premature ovarian failure and infertility as a sequel to the treat

27 female mice, the event that drives premature ovarian failure and infertility in female cancer patient

28 ous disorder that leads to hypergonadotropic ovarian failure and infertility.

29 menopause is thought to be caused solely by ovarian failure and oocyte depletion.

30 exposure of females to BaP causes premature ovarian failure and ovarian tumorigenesis and that embry

31 However, both VCD-induced ovarian failure and OVX led to a dramatic reduction in t

32 omatic component most likely account for the ovarian failure and short stature.

33 (AOD) is a probable cause of human premature ovarian failure, and a potential complication of contrac

34 es of Turner syndrome include short stature, ovarian failure, and a variety of other anatomic and phy

35 be at risk of uterine artery embolization or ovarian failure, and in those in whom the ovarian artery

36 increased destruction of oogonia, premature ovarian failure, and ovarian tumorigenesis after transpl

37 gressive external ophthalmoplegia, premature ovarian failure, and Parkinson's disease.

38 sm spectrum disorder in childhood, premature ovarian failure, and the neurodegenerative disorder, fra

39 eficits on the fragile-X spectrum; premature ovarian failure; and a newly described, neurodegenerativ

40 asing hormone agonists, chemotherapy-induced ovarian failure, androgen deprivation therapy, and aroma

41 ng the "postmenopausal" stage of accelerated ovarian failure (AOF) in young female mice treated with

42 Acute ovarian failure (AOF) occurred in 6.3% of eligible survi

43 A new rodent model of accelerated ovarian failure (AOF) successfully replicates human peri

44 Short stature and ovarian failure are characteristic features of Turner's

45 The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined

46 and survivors are at high risk for permanent ovarian failure at a young age.

47 survivors included older age at assessment, ovarian failure at a younger age, treatment with cranial

48 s, the development of methods for postponing ovarian failure at menopause may represent an attractive

49 The fourth patient had premature ovarian failure at the age of 13 years.

50 One had had premature ovarian failure at the age of 14 years, whereas her sist

51 Chemotherapy-induced ovarian failure causes rapid and highly significant bone

52 l ovotoxicants plays a role in the premature ovarian failure commonly associated with infertility and

53 Premature ovarian failure curtails female reproductive life and is

54 the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the

55 The oldest sibling had primary ovarian failure diagnosed at age 14.5 years.

56 ozygous mutant females displayed a premature ovarian failure due to a depletion of the germ cell pool

57 linical end points: development of premature ovarian failure, end-stage renal disease (ESRD), doublin

58 ulation is depleted through natural cycling, ovarian failure follows increasing periods of acyclity.

59 et of Chinese women with sporadic, premature ovarian failure harbor mutations in FIGLA.

60 iable spectrum of somatic features including ovarian failure, heart and renal abnormalities, microgna

61 These traits included short stature, ovarian failure, high-arched palate, and autoimmune thyr

62 mong the 35 women who were defined as having ovarian failure, highly significant bone loss was observ

63 ally occurring BMP15 mutation leads to early ovarian failure in humans, and BMP15 has been shown to a

64 tened reproductive lifespan, as in premature ovarian failure in humans.

65 aluable for predicting the risk of premature ovarian failure in lupus nephritis patients treated with

66 toimmune ovarian disease (AOD) and premature ovarian failure in neonatal, but not adult, mice.

67 herapy and radiation may result in premature ovarian failure in premenopausal oncology patients.

68 ng Nobox in a manner similar to nonsyndromic ovarian failure in women.

69 Premature ovarian failure is a common consequence of systemic trea

70 Ovarian failure is a common toxic effect of chemotherapy

71 Premature ovarian failure is a major cause of female infertility.

72 ndergo a true menopause, female mice exhibit ovarian failure long before death because of chronologic

73 The time at which ovarian failure (menopause) occurs in females is determi

74 Oocyte destruction and ovarian failure occur in PAH-treated mice, and cigarette

75 evaluate the effects of chemotherapy-induced ovarian failure on bone loss and markers of skeletal tur

76 alkylators can place women at risk for acute ovarian failure or premature menopause and men at risk f

77 The genetic causes of premature ovarian failure (POF) are highly heterogeneous, and caus

78 ung women who are facing a risk of premature ovarian failure (POF) caused by radiation or chemotherap

79 or an SNP on MCM8 associated with premature ovarian failure (POF) diminishes the functional activity

80 nsanguineous family with inherited premature ovarian failure (POF) identified a homozygous frameshift

81 d not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may

82 ations cause gonadal dysgenesis or premature ovarian failure (POF) in women, as well as eyelid/forehe

83 Premature ovarian failure (POF) is a genetically and phenotypicall

84 Premature Ovarian Failure (POF) is a genetically heterogenous diso

85 Premature ovarian failure (POF) is characterized by amenorrhea and

86 Premature ovarian failure (POF) is characterized by elevated gonad

87 Premature ovarian failure (POF) is genetically heterogeneous and m

88 he impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, includi

89 The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone

90 bly high incidence of irreversible premature ovarian failure (POF).

91 lkylating agent doses were at risk for acute ovarian failure, premature menopause, and small-for-gest

92 We reviewed the frequency of acute ovarian failure, premature menopause, live birth, stillb

93 35 with complete primary end-point data, the ovarian failure rate was 8% in the goserelin group and 2

94 ith chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause an

95 ificantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence inte

96 yopathy; demyelinating neuropathy; premature ovarian failure; short stature; hearing loss; pigmentary

97 east cancer who develop chemotherapy-induced ovarian failure should have their bone density monitored

98 ocytes resemble those of the human premature ovarian failure syndrome.

99 in relation to models that ascribe premature ovarian failure to interruption of ovarian genes or to a

100 oid loss, ovariectomy and chemically-induced ovarian failure, to evaluate kainate-induced seizure act

101 Chemotherapy-induced ovarian failure was defined as a negative pregnancy test

102 nsanguineous family with inherited premature ovarian failure, we identified a homozygous 1-bp deletio